Ventripoint Diagnostics 관리

관리 기준 확인 1/4

Ventripoint Diagnostics CEO는 Hugh MacNaught, Feb2024 에 임명되었습니다 의 임기는 1년 미만입니다. 는 € 5.50K 가치에 해당하는 회사 주식의 0.037% 직접 소유합니다. 5.50K. 경영진과 이사회의 평균 재임 기간은 각각 1.1 년과 4.2 년입니다.

주요 정보

Hugh MacNaught

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	0.04%
경영진 평균 재임 기간	1.1yrs
이사회 평균 재임 기간	4.2yrs

최근 관리 업데이트

Recent updates

CEO

Hugh MacNaught

less than a year

테뉴어

CA$37,633

보상

Mr. Hugh MacNaught served as an Independent Director at VentriPoint Diagnostics Ltd since September 2020 and serves as its Interim CEO, President & Director since February 2024. He served as an Executive V...

리더십 팀

이름	위치	테뉴어	보상	소유권
George Adams	Executive Chairman & Corporate Secretary	14.1yrs	CA$346.83k	0.40% € 59.0k
Hugh MacNaught	Interim CEO	less than a year	CA$37.63k	0.037% € 5.5k
Jimmy Jeon	Chief Financial Officer	1.1yrs	데이터 없음	데이터 없음
Hirotaka Katagiri	CTO & Business Development Division Director	3.8yrs	데이터 없음	데이터 없음
Matt Dobson	Marketing Director	less than a year	데이터 없음	데이터 없음
Jim Graba	Application Specialist & Chief Trainer	6.5yrs	데이터 없음	데이터 없음
Bart Hendriks	Strategic Partnership Executive	no data	데이터 없음	0% € 0

1.1yrs

평균 재임 기간

경험이 풍부한 관리: 5V7 의 관리팀은 경험 (평균 재직 기간 1.1 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
George Adams	Executive Chairman & Corporate Secretary	14.1yrs	CA$346.83k	0.40% € 59.0k
Hugh MacNaught	Interim CEO	4.2yrs	CA$37.63k	0.037% € 5.5k
Robert Hodgkinson	Member of Business Advisors	less than a year	CA$18.14k	0% € 0
Samuel Schwartz	Chair of Business Advisory Committee	6.7yrs	데이터 없음	데이터 없음
Scott D. Solomon	Member of Scientific Advisory Board	12.7yrs	데이터 없음	데이터 없음
Randy AuCoin	Independent Director	2.9yrs	CA$99.20k	데이터 없음
David Sahn	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Mark Lewin	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Michael Gatzoulis	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Richard Krasuski	Member of Scientific Advisory Board	13.5yrs	데이터 없음	데이터 없음
Fiona Fitzgerald	Independent Director	3.1yrs	CA$113.18k	데이터 없음
Gregory Skinner	Member of Board of Clinical Advisors	2.8yrs	데이터 없음	데이터 없음

4.2yrs

평균 재임 기간

경험이 풍부한 이사회: 5V7 의 이사회는 경험(평균 재직 기간 4.2 년)으로 간주됩니다.

Ventripoint Diagnostics 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Ventripoint Diagnostics Ltd. Appoints Hugh Macnaught as President

VentriPoint Diagnostics Ltd. Announces Appointment of Dr. Luc Mertens to Clinical Advisory Board

VentriPoint Diagnostics Ltd. Announces Executive Changes

Less than half of directors are independent

Ventripoint Diagnostics Ltd. Announces Appointment of Alvira Macanovic as President

VentriPoint Diagnostics Ltd., Annual General Meeting, Aug 16, 2022

Recent updates

Ventripoint Diagnostics Ltd. announced that it has received CAD 1.554925 million in funding

New minor risk - Shareholder dilution

Ventripoint Diagnostics Ltd. Receives EU CE Mark for Next Generation, AI-Powered Heart-Scanning Technology

Ventripoint Diagnostics Ltd. Submits its Next Generation of Software and Hardware, VMS+4.0

Second quarter 2024 earnings released: CA$0.009 loss per share (vs CA$0.007 loss in 2Q 2023)

Ventripoint Diagnostics Ltd. announced that it expects to receive CAD 3.5 million in funding

Ventripoint Diagnostics Ltd. announced that it expects to receive CAD 3.5 million in funding

Ventripoint Diagnostics Ltd. Receives Medical Device License from Health Canada

First quarter 2024 earnings released: CA$0.008 loss per share (vs CA$0.009 loss in 1Q 2023)

Full year 2023 earnings released: CA$0.031 loss per share (vs CA$0.031 loss in FY 2022)

VentriPoint Diagnostics Ltd. announced that it expects to receive CAD 3 million in funding

Ventripoint Diagnostics Ltd. Appoints Hugh Macnaught as President

VentriPoint Diagnostics Ltd. Announces Appointment of Dr. Luc Mertens to Clinical Advisory Board

VentriPoint Diagnostics Ltd. to Report Q3, 2023 Results on Nov 29, 2023

VentriPoint Diagnostics Ltd. Announces Executive Changes

VentriPoint Diagnostics Ltd. to Report Q2, 2023 Results on Aug 29, 2023

Ventripoint Diagnostics Ltd. Announces That Ventripoint and Ascend Cardiovascular, Llc Have Developed A New Integrated Product

VentriPoint Diagnostics Ltd. to Report Q1, 2023 Results on May 30, 2023

Less than half of directors are independent

Ventripoint Diagnostics Ltd. Announces Appointment of Alvira Macanovic as President

VentriPoint Diagnostics Ltd. Relocates to New Facility in Toronto

VentriPoint Diagnostics Ltd., Annual General Meeting, Aug 16, 2022

Less than half of directors are independent

Ventripoint Appoints Dr. Gregory Skinner to Board of Clinical Advisors

Less than half of directors are independent

High number of new and inexperienced directors

Full year 2020 earnings released: CA$0.025 loss per share (vs CA$0.052 loss in FY 2019)

Ventripoint Diagnostics Ltd.'s Heart Analysis System to Be Used at the Stollery Children's Hospital to Study Atrial Dysfunction in Children

New 90-day high: €0.23

New 90-day high: €0.22

Independent Director recently sold €56k worth of stock

Ventripoint Diagnostics Ltd. Enters into A Collaboration Agreement with the Veterinary Hospital At the North Carolina State University

Kings College London Receives VMS+3.0 Ventripoint Whole Heart Analysis System

Executive Chairman & CEO recently sold €136k worth of stock

Ventripoint Diagnostics Ltd. Installs Whole Heart Analysis System in MD Anderson Cancer Center in Houston

Ventripoint Diagnostics Ltd. Remotely Installs Whole Heart Analysis System in Major European Hospital

Ventripoint Diagnostics Ltd. Appoints Hugh MacNaught as Director of the Corporation

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간